A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.


Updates from The Motley Fool

Latest updates on Amgen from Fool.com.  The Fool has written over 800 articles on Amgen.
Better Buy: Amgen vs. Biogen

These cash-flow monsters are trading on the cheap. Which is the better bet for new money today?

Is Amgen a Buy?

There's good news and there's bad news for this big biotech.

Is Amgen Inc. a Buy?

Amgen is on a roll in 2018. But can the biotech's momentum continue?

Better Buy: Biogen Inc. vs. Amgen

Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearl...



Stock Performance

View Interactive AMGN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Amgen.
Current Price: $191.24
Prev Close: $191.24
Open: $0.00
Bid: $189.87
Ask: $192.88
Day's Range: $0.00 - $0.00
52wk Range: $163.31 - $210.19
Volume: 183
Avg Vol 3,046,537
Market Cap: $139B
P/E (ttm): 15.15
EPS (ttm): $12.62
Div & Yield: $4.60 (3.0%)

Company Rating

What our community thinks about Amgen.
CAPS Rating 5 out of 5
 
2218 Outperform
169 Underperform
CAPS All Stars
 
565 Outperform
23 Underperform

How do you think Amgen will perform against the market?



You pick for Amgen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Robert A. Bradway, CEO

77% Approve

Based on 622 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Amgen.

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers